At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
CC-10004drug
Likely dose
CC-10004 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
In Brief
A Phase 2 clinical trial evaluating CC-10004 for Prostatitis and Chronic Prostatitis With Chronic Pelvic Pain Syndrome. Completed, enrolled 21 participants across 1 site.
Detailed Summary
Prostatitis is the most common urologic diagnosis in men under the age of 50 and the third most common diagnosis in older men. In Chronic Prostatitis (CP) or Chronic Pelvic Pain Syndrome (CPPS), men have lower urinary tract symptoms, pelvic pain, sexual dysfunction and decreased quality of life. Little is known about the cause of CP/CPPS. Likewise, no definitive therapy exists for CP/CPPS. We plan to study the use of CC-10004 in men with CP/CPPS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsCelgene Corporation
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedJun 2008
Primary CompletionJan 2011
Study CompletionMar 2011
TodayJul 2026
First PostedJun 19, 2008
Enrollment StartJun 1, 2008
Primary CompletionJan 1, 2011
Study CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 18.0 years ago
Interventions
CC-10004drug
CC-10004 20 mg per day